Market News
Pfizer Vaccine Partially Protects Against New COVID-19 Variant

Pfizer Vaccine Partially Protects Against New COVID-19 Variant

08-12-2021 15:22

ZFX – Studies show that the Pfizer vaccine can only partially protect against the Omicron variant.

The Omicron variant of the coronavirus could partially evade protection from two doses of Pfizer Inc (NYSE:PFE) and partner BioNTech’s COVID-19 vaccine, the head of laboratory research at the African Health Research Institute in South Africa said Tuesday.

However, research shows that blood from people who have received two doses of the vaccine and have had a previous infection are mostly able to neutralize the variant, suggesting that booster doses of the vaccine may help to fend off infection.

Alex Sigal, a professor at the African Institute of Health Research, said on Twitter (NYSE:TWTR) there was a “huge drop” in neutralization of the Omicron variant relative to previous COVID-19 strains.

The lab tested the blood of 12 people who had been vaccinated with two doses of the Pfizer/BioNTech vaccine, according to a manuscript posted on its lab website. Initial data in the manuscript has not been peer reviewed.

Blood from five of the six people who had been vaccinated and previously infected with COVID-19 still neutralized the Omicron variant, the manuscript said.

“This result is better than I expected. The more antibodies you get, the more likely you are to be protected against Omicron,” Sigal said on Twitter.

He said the laboratory had not tested the variant against blood from people who had received the booster dose, as it was not yet available in South Africa.

According to the manuscript, the laboratory observed a 41-fold decrease in neutralizing antibody levels against the Omicron variant.

Sigal said on Twitter that the figure would likely be adjusted once his lab does more experiments.

While neutralizing antibodies are an indicator of the body’s immune response, scientists believe other cell types such as B cells and T cells are also stimulated by the vaccine and help protect against the effects of the coronavirus.

Preliminary data do not indicate that the vaccine is less able to prevent severe illness or death. While lab tests are ongoing, BioNTech CEO Ugur Sahin said last week “we think it’s likely people will have substantial protection against severe disease caused by Omicron.”

The Omicron variant, first detected in southern Africa last month, has sparked alarm globally of another spike in infections, with more than two dozen countries from Japan to the United States reporting cases.

The World Health Organization classified it on Nov. 26 as a “variant of concern,” but said there was no evidence to support the need for a new vaccine specifically designed to tackle the Omicron variant with its multiple mutations.

There is no significant data yet on how vaccines from Moderna (NASDAQ:MRNA), Johnson & Johnson (NYSE:JNJ) and other drugmakers are holding up against the new variant. All manufacturers, including Pfizer and BioNTech, are expected to release their own data in a few weeks.

BioNTech’s Sahin told NBC News on Tuesday that the drug-maker has data coming Wednesday or Thursday regarding the new variant.

Leading US infectious disease expert Dr. Anthony Fauci said Tuesday that preliminary evidence suggests that the Omicron variant of the coronavirus may have a higher rate of transmission but is less severe.

He said the United States was conducting its own tests to determine current vaccine protection against the variant and expected results next week.

Umer Raffat, an analyst for Evercore ISI, cautions against reading too much into one study, noting there is significant variability in measuring decreased antibody levels in previous laboratory studies.

“We are waiting for additional studies to draw the mosaic,” he said.

Risk Warning: The above content is for reference only, and does not represent ZFX’s position. ZFX does not assume any form of loss caused by any trading operations carried out in accordance with this article. Please be firm in your thinking and do the corresponding risk control.

ZFX (Zeal Capital Market) is an FCA & FSA licensed online Forex & CFD broker providing more than 100 products for Forexcommoditiesstock indices, and share CFDsOpen a trading account with min. USD 50 deposit and download our MT4 trading platform now!